Microbiology and infectious disease testing represent one of the largest and most dynamic application segments in IVD. The shift from traditional culture-based microbiology to molecular-based syndromic testing is accelerating, driven by the need for faster time-to-result, broader pathogen coverage from a single sample, and stewardship of antimicrobial therapy. BioFire Diagnostics received FDA 510(k) clearance for its FilmArray Gastrointestinal Panel Mid in January 2025. The IVD industry is witnessing a decisive shift from single-pathogen to syndromic testing panels that simultaneously detect multiple pathogens linked to a specific clinical syndrome. Antimicrobial resistance diagnostics — identifying resistant organisms including MRSA, CRE, and VRE directly from clinical samples — is a rapidly growing sub-segment driven by global AMR stewardship programs. COVID-19 demonstrated the critical role of IVD in outbreak response at population scale, creating permanent investment in rapid molecular infrastructure.

This report provides significant competitor information, analysis...

Roche Diagnostics is the world's largest IVD company with revenues of approximately $17 billion in 2025, operating across immunoassay, clinical chemistry, molecular diagnostics, tissue diagnostics, and point-of-care testing. Roche's cobas series — encompassing the cobas 8000 and cobas infinity digital health platform — is the installed base leader in high-volume core laboratories globally. The NAVIFY digital pathology platform delivers AI-powered tissue analysis. Roche's partnerships with pharmaceutical companies for companion diagnostics have created a structurally growing revenue stream as precision oncology drug approvals accelerate. The company holds a leading position in hospital systems, reference laboratories, and blood screening globally.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — cobas Platform Expansion, Digital Pathology, and CDx Growth Through 2030
• Financial Performance...

Abbott Diagnostics generates approximately $12 billion in IVD revenues in 2025, with leading positions in immunoassay, clinical chemistry, molecular diagnostics, and point-of-care testing across its Core Laboratory and Rapid Diagnostics divisions. The Alinity family — Alinity c for clinical chemistry, Alinity i for immunoassay, and Alinity m for molecular — represents Abbott's fully integrated laboratory automation strategy. The ID NOW platform received CE marking for its 2.0 enhanced version in January 2025, optimized for COVID-19 and flu dual detection, with over 50,000 instruments deployed globally. Abbott's BinaxNOW rapid antigen portfolio demonstrated the commercial power of decentralized diagnostics at population scale. Abbott reports 9.5-10% organic sales growth with $1.65-$1.68 billion in Q1 2025 revenue guidance.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — Alinity Consolidation, I...

Danaher's diagnostics platform generates approximately $8 billion in IVD revenues in 2025, comprising Beckman Coulter Diagnostics in clinical chemistry and immunoassay, Cepheid in molecular diagnostics, Radiometer in critical care and blood gas testing, and Leica Biosystems in anatomic pathology and digital pathology. Cepheid's GeneXpert platform — with over 50,000 installed instruments across more than 180 countries — is the global leader in near-patient molecular testing for tuberculosis, HIV, hepatitis, and infectious disease syndromic panels. Beckman Coulter's DxC series competes directly with Roche cobas, Abbott Alinity, and Siemens Atellica for core laboratory consolidation. Leica Biosystems positions Danaher at the forefront of computational pathology.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — GeneXpert Expansion, Core Lab Consolidation, and Digital Pathology Through 2030
• F...

Siemens Healthineers generates approximately $7 billion in IVD revenues in 2025 through its Diagnostics division, encompassing clinical chemistry, immunoassay, hematology, molecular diagnostics, and urinalysis. The Atellica Solution — Siemens Healthineers' fully integrated immunoassay and clinical chemistry platform — is the company's primary core laboratory consolidation vehicle. Siemens Healthineers is investing significantly in AI-powered diagnostics and digital health through its teamplay digital health platform, connecting laboratory devices, clinical decision support, and remote service capabilities. The company has a strong presence in European hospital laboratories and is expanding in Asia-Pacific emerging markets.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — Atellica Expansion, AI-Powered Diagnostics, and Digital Health Through 2030
• Financial Performance — Revenue, Revenue...

bioMérieux is a French IVD company specializing in microbiology, molecular diagnostics, and applied microbiology for food and pharmaceutical testing, with revenues of approximately $4.5 billion in 2025. The company is the global leader in automated blood culture (BacT/ALERT), clinical microbiology (VITEK), and molecular syndromic testing (BIOFIRE FilmArray). The BIOFIRE FilmArray syndromic panels — covering respiratory, gastrointestinal, blood culture identification, meningitis/encephalitis, and pneumonia — are the market-leading multiplex molecular syndromic testing platforms globally. bioMérieux's acquisition of SpinChip in 2024 secured a beachhead in microfluidics-based near-patient testing. The applied microbiology business serves pharmaceutical quality control and food safety testing markets.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — BIOFIRE Expansion, Microbiology Leadership, and...

Sysmex is a Japanese IVD company and the global leader in hematology analyzers, with revenues of approximately $4 billion in 2025 spanning hematology, hemostasis, urinalysis, and life science. Sysmex holds the dominant global market share in automated hematology — complete blood count, 5-part differential, and reticulocyte analysis — with installed bases across hospital laboratories, reference laboratories, and physician office laboratories worldwide. Sysmex is identified as an Emerging Leader in the broader IVD market, gaining traction through specialized analyzers and automation-driven solutions. Digital morphology — AI-powered blood film analysis enabling remote blood cell classification — is Sysmex's primary next platform growth vector.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — Hematology Dominance, Digital Morphology, and Molecular Expansion Through 2030
• Financial Perform...

QuidelOrtho was formed by the 2022 merger of Quidel and Ortho Clinical Diagnostics, creating a combined IVD company with revenues of approximately $3 billion in 2025. QuidelOrtho operates across rapid diagnostics, transfusion medicine, and clinical laboratory testing. The Sofia platform and BinaxNOW co-distributed products were deployed at unprecedented scale during COVID-19. Ortho's Vitros platform competes in the immunoassay and clinical chemistry core laboratory segment. QuidelOrtho's transfusion medicine business serves blood banks and hospital transfusion services with immunohematology analyzers and reagents. The company is navigating post-COVID volume normalization in rapid testing while investing in integration of the merged portfolios and expanding internationally.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — Post-Merger Integration, Rapid Diagnostics Recovery, and Transfusion Medicine ...

Hologic is a U.S.-based IVD and medical device company with revenues of approximately $2.5 billion in diagnostics in 2025, specializing in women's health, molecular diagnostics, and surgical products. Hologic's Panther and Panther Fusion platforms are market leaders in women's health molecular testing — cervical cancer screening (HPV and Pap), STI testing (chlamydia, gonorrhea, trichomonas), and reproductive health diagnostics. The company holds a leading position in blood screening through its TMA molecular technology. Hologic's diagnostics business benefits from a large, captive installed base of Panther instruments globally, with recurring reagent revenue providing strong aftermarket economics.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — Panther Menu Expansion, Women's Health Leadership, and Blood Screening Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue...

Bio-Rad Laboratories is a U.S.-based IVD and life science company with revenues of approximately $2.4 billion in 2025 across clinical diagnostics and life science research. Bio-Rad's clinical diagnostics segment specializes in quality controls, blood typing, diabetes monitoring (HbA1c), autoimmune testing, and infectious disease serology. The company is the global leader in laboratory quality controls — a high-margin, recurring revenue business supplying calibrators and controls to virtually every clinical laboratory globally. Bio-Rad accepted a binding offer to acquire Stilla Technologies in February 2025, expanding into digital PCR. The company's Droplet Digital PCR technology is gaining adoption in oncology research and liquid biopsy applications.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — Quality Controls Leadership, Digital PCR Expansion, and Autoimmune Testing Through 2030
• Fina...

DiaSorin is an Italian specialty IVD company with revenues of approximately $1.5 billion in 2025, specializing in immunoassay for specialty testing, molecular diagnostics, and clinical chemistry. DiaSorin is the global leader in vitamin D testing — a dominant market position in a high-volume specialty immunoassay segment — and holds strong positions in infectious disease serology, bone metabolism, and endocrinology testing. The company's 2021 acquisition of Luminex significantly expanded its molecular diagnostics portfolio, adding multiplex syndromic testing and flow cytometry-based immunoassay platforms. DiaSorin's LIAISON platform is deployed in immunoassay laboratories globally.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Strategic Directions — Specialty Immunoassay Leadership, Luminex Integration, and Molecular Expansion Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Ge...